Search
Almasilate
go.drugbank.com/drugs/DB13595ApprovedGiven that there are generally more widely available conventional antacids that are just as - if not more - effective than almasilate, almasilate products are only available in certain parts of Europe … Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia.
Padimate A
go.drugbank.com/drugs/DB11229ApprovedWithdrawnIn Europe this chemical was withdrawn in 1989 for unstated reasons and in the US it was never approved for use in sunscreens.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Capsaicin
go.drugbank.com/drugs/DB06774ApprovedInvestigationalThe most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia. … Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements
Mixtures: CapsFenac Pak, Sure Result DSS Premium PakMemantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalIn 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. … It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease
Products: PMS-memantineVoxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Sibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnSibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. … It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States.
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380,L10971] Lonapegsomatropin was granted FDA approval on 25 August 2021.[L36380] It was later approved by the European Commission on 13 January 2022.[L39900] … [A237605,L36380,L36405] Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administered as a single weekly dose.
Chondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceutical[A32063] Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.[A32066] … [A7906] The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment.
Aripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigational[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136] … [L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.
Products: PMS-aripiprazole